 Immunotherapy, Adoptive
"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 2 | 4 | | 2003 | 2 | 0 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 1 | 2 | | 2010 | 2 | 1 | 3 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 3 | 6 | | 2013 | 4 | 1 | 5 | | 2014 | 8 | 4 | 12 | | 2015 | 6 | 4 | 10 | | 2016 | 10 | 3 | 13 | | 2017 | 7 | 3 | 10 | | 2018 | 12 | 3 | 15 | | 2019 | 19 | 4 | 23 | | 2020 | 15 | 4 | 19 | | 2021 | 17 | 13 | 30 | | 2022 | 5 | 17 | 22 | | 2023 | 4 | 25 | 29 | | 2024 | 14 | 9 | 23 | | 2025 | 37 | 1 | 38 | | 2026 | 11 | 3 | 14 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Elghawy O, Reef D, Gorzewski A, Wang J, Shouse G, Reinert C, Teferra A, Velez ET, Pelcovits A, Ollila T, Clark W, Yazbeck V, Maakaron J, Kamdar M, Fitzgerald L, Danilov A, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N. Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study. Blood Adv. 2026 Jun 09; 10(11):3757-3768.
-
Bermack C, Singh S, Pei G, Patel SP, Wang L, Yee C. First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study. J Immunother Cancer. 2026 Apr 30; 14(4).
-
Kim D, Moon SJ, Han EL, Feng E, Murray AM, Wang J, Liu W, Kong G, June CH, Mitchell MJ. HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering. Nano Lett. 2026 May 06; 26(17):5668-5679.
-
Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee A, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang A, Barsouk A, Cho JH, Shaw CE, Singh E, Ugwuanyi O, Paruzzo L, Stella F, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey A, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M. Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies. Blood. 2026 Apr 16; 147(16):1842-1856.
-
Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin I, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu S, Wagner-Johnston N, Ollila TA, Grover N, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov A, Tun H, Munoz J, Narkhede M, Rhodes JM, Prica A, Kuhnl A, Maraj A, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Baidoun F, Monick SE, Trutzer IM, Can J, Ayers A, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K. Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma. Blood. 2026 Apr 16; 147(16):1814-1827.
-
Shen S, Mohan AA, Hotchkiss KM, Cook S, Patel K, Moelker E, Puviindran B, Gonzalez AT, Zaidi S, Spellicy S, Schwartz A, Suryadevara C, Wilkinson D, Ayasoufi K, Fecci PE, Sanchez-Perez L, Sampson J, Patel A. IL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma. J Immunother Cancer. 2026 Mar 24; 14(3).
-
Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ. Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium. Blood Cancer J. 2026 Mar 20; 16(1).
-
Dreyzin A, Yates B, Shalabi H, Silbert SK, Wang HW, Yuan CM, Hoang CN, Culbert AA, Gava F, Nair MS, Giordani VM, Little L, Foley T, Nussenblatt V, Fry TJ, Stroncek DF, Highfill SL, Shah NN. Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2026 Mar 10; 10(5):1700-1712.
-
Cardus O, Mañé Pujol J, de Daniel A, Moreno DF, Oliveira TGM, Battram AM, Salsench SV, Perez-Amill L, Llobregat H, Carpio Mármol J, Martin-Antonio B, Oliver-Caldes A, Munárriz D, Juan M, Urbano-Ispizua A, Rodríguez-Lobato LG, Fernández de Larrea C. Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain. J Immunother Cancer. 2026 Mar 03; 14(3).
-
Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, García-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet. 2026 Mar 07; 407(10532):963-975.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|